www.jhoonline.org

Table 1
Summary of targets, toxicity, and evaluation at ASCO 2008 of novel agents in advanced breast cancer.
Agent	Target	Toxicity	Evaluation at ASCO

Lapatinib	EGFR/HER2	Diarrhea, rash, nausea, vomiting	-monotherapy in inflammatory BC
			-c/w trastuzumab
			-c/w bevacizumab

HKI-272	Pan HER	Diarrhea, nausea	n/a

Trastuzumab DM-1	HER2	Transaminitis, fatigue, thrombocytopenia, anemia, neuropathy	-monotherapy refractory to trastuzumab

Pertuzumab	HER2	Diarrhea, pain, nausea, vomiting, mucositis	-c/w trastuzumab

Tanespimycin	HSP 90	Fatigue, diarrhea, dizziness, headache	-c/w trastuzumab

Cetuximab	EGFR	Rash, diarrhea, nausea, vomiting	-c/w carboplatin in triple negative BC
			-c/w irinotecan

Bevacizumab	VEGF	Hypertension, proteinuria, bleeding, thromboembolism	-c/w lapatinib
			-c/w docetaxel
			-c/w nab-paclitaxel

Gefitinib	EFGR	Rash, diarrhea, nausea, vomiting	-c/w anastrazole

RAD001	mTOR	Stomatitis, fatigue, anorexia, diarrhea, headache, rash	-c/w anastrazole
			-c/w paclitaxel and trastuzumab
			-c/w navelbine and trastuzumab

Pazopanib	VEGFR, PDGFR, C-kit	Diarrhea, rash, nausea	-c/w lapatinib

Sunitinib	VEGFR, PDGFR, C-kit	Mucositis, fatigue, nausea, diarrhea	n/a

Axitinib	VEGFR 1,2, PDGFR, C-kit	Diarrhea, nausea, alopecia, stomatitis	n/a

C1311	Topoisomerase II	Neutropenia	-monotherapy in refractory BC

Pemetrexed	Anti-folate	Myelosuppression, anemia	-1^stline monotherapy in advanced BC

Larotaxel	Cytotoxic	Neutropenia, fatigue	-c/w trastuzumab

Orataxel	Cytotoxic	Neutropenia, fatigue, peripheral neuropathy	-monotherapy in taxane resistant BC

Abbreviations: ASCO; American Society of Clinical Oncology; EGFR, epidermal growth factor receptor; HER, human epidermal receptor; BC, breast cancer; c/w, combination with; n/a, not applicable; HSP, heat shock protein; VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor
Chu and Lu Journal of Hematology & Oncology 2008 1:16 doi:10.1186/1756-8722-1-16

Table 1